EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access

Outcomes of early‐treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study

Natalie L Goedeker iD, Amanda Rogers, Mark Fisher, Kapil Arya, John F Brandsema, Hiba Farah, Michelle A Farrar, Marcia V Felker, Melissa Gibbons, Omer Abdul Hamid, Matthew Harmelink, Karen Herbert und 9 weitere

Muscle & Nerve · 2024-12 · 70 (6) · 1247-1256

DOI: 10.1002/mus.28267 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Muscle & Nerve, online erschienen am 06.10.2024. Verfasst von Natalie L Goedeker und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Survival of Motor Neuron 2 Protein, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims While prompt identification and treatment of infants with spinal muscular atrophy (SMA) can ameliorate outcomes, variability persists. This study assessed management and outcomes of early‐treated infants with SMA.

Methods

We analyzed retrospective data at 12 centers on infants with SMA treated at age ≤6 weeks from August 2018 to December 2023.

Results

Sixty‐six patients, 35 with two SMN2 copies and 31 with ≥3 SMN2 copies, were included. Twenty‐five (38%, 22 with two SMN2 copies), had SMA findings before initial treatment which was onasemnogene abeparvovec in 47 (71%) and nusinersen in 19 (29%). Thirty‐two received sequential or combination treatments, including 16 adding nusinersen or risdiplam due to SMA findings following onasemnogene abeparvovec. All sat independently. Compared to children with ≥3 SMN2 copies, those with two SMN2 copies were less likely to walk (23/34 [68%] vs. 31/31 [100%], p < .001) and less likely to walk on time (9/34 [26%] vs. 29/31 [94%], p < .001); one non‐ambulatory child was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Survival of Motor Neuron 2 ProteinMuscular Atrophy, SpinalHumansRetrospective StudiesMaleInfantFemaleTreatment OutcomeInfant, NewbornOligonucleotidesCohort StudiesSpinal Muscular Atrophies of ChildhoodRecombinant Fusion ProteinsAzo CompoundsBiological ProductsPyrimidines

Stichwörter der Autor:innen

CHOP INTENDnewborn screeningnusinersenonasemnogene abeparvovecspinal muscular atrophy

Substanzen

nusinersenSurvival of Motor Neuron 2 ProteinOligonucleotidesSMN2 protein, humanZolgensmaRecombinant Fusion ProteinsRisdiplamAzo CompoundsBiological ProductsPyrimidines

Autor:innen und Institutionen

  • Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Department of Pediatrics, Norton Children's Medical Group, University of Louisville, Louisville, Kentucky, USA.
  • Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
  • Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, USA.
  • Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Sydney Children's Hospital Network and Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine, UNSW Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Natalie L Goedeker, Aravindhan Veerapaniyan

Förderung

  • NCATS NIH HHS
  • National Institutes of Health (NIH)
  • National Center for Advancing Translational Sciences (NCATS)

Zitieren

APA

Goedeker, N. L., Rogers, A., Fisher, M., Arya, K., Brandsema, J. F., Farah, H., Farrar, M. A., Felker, M. V., Gibbons, M., Hamid, O. A., Harmelink, M., Herbert, K., Kichula, E., King, K., Lakhotia, A., Lee, B. H., Kuntz, N. L., Parsons, J., Rehborg, R., …, & Zaidman, C. M. (2024). Outcomes of early‐treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study. Muscle & Nerve, 70(6), 1247-1256. https://doi.org/10.1002/mus.28267

Vancouver

Goedeker NL, Rogers A, Fisher M, Arya K, Brandsema JF, Farah H, et al. Outcomes of early‐treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study. Muscle & Nerve. 2024;70(6):1247-1256. doi:10.1002/mus.28267

BibTeX
@article{Goedeker2024,
  author = {Goedeker, Natalie L and Rogers, Amanda and Fisher, Mark and Arya, Kapil and Brandsema, John F and Farah, Hiba and Farrar, Michelle A and Felker, Marcia V and Gibbons, Melissa and Hamid, Omer Abdul and Harmelink, Matthew and Herbert, Karen and Kichula, Elizabeth and King, Kiana and Lakhotia, Arpita and Lee, Bo Hoon and Kuntz, Nancy L and Parsons, Julie and Rehborg, Rebecca and Veerapaniyan, Aravindhan and Zaidman, Craig M},
  title = {Outcomes of early‐treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study},
  journal = {Muscle & Nerve},
  year = {2024},
  volume = {70},
  number = {6},
  pages = {1247--1256},
  doi = {10.1002/mus.28267}
}
Kostenlos starten →